Titan Biotech Goes Ex-Bonus for 1:4 Issue as Stock Surges 4,700%+ in a Decade

Titan Biotech Limited traded ex-bonus on Friday following its earlier declaration of a bonus issue in the ratio of 1:4. The company fixed Friday, 23 October, as the record date to determine eligible shareholders for the corporate action.

Bonus Issue Terms and Price Adjustment

Shares of Titan Biotech closed at ₹417.15 on Thursday. Factoring in the bonus ratio—which grants one complimentary share for every four shares of ₹2 face value held—the stock opened on the BSE on Friday at an adjusted base price of ₹335.35, recording minor gains during the trading session.

Only investors who held at least four shares in their demat accounts as of the close of trading on Thursday qualify for the bonus issuance; shares purchased on or after the ex-bonus date are not eligible.

Historical Returns and Market Performance

The stock has outperformed broader market benchmarks across multiple horizons:

• Short-Term Gains: Up approximately 6% over the past month and 98% year-to-date in 2026, contrasting with a decline of over 13% in the Sensex during the same period.
• Medium to Long-Term Returns: The scrip has delivered returns of 126% over two years, 487% over three years, and 590% across the five-year timeframe.
• Decade Performance: Long-term positional investors have seen a multi-bagger surge of 4,754% over 10 years.

Prior Corporate Actions

Earlier in the year, Titan Biotech executed a 1:5 stock split, subdividing the face value of each equity share from ₹10 down to ₹2. Additionally, the stock traded ex-dividend in September 2026, distributing an interim dividend of ₹0.50 per equity share to its investors.

Disclaimer: This is not investment advice. The stock market is subject to market risks. Please exercise prudence and conduct your own research, or consult a certified financial advisor, before making any investment decisions. newseyeview.com does not recommend the purchase or sale of any stocks based on this information.